CTLA-4-Ig, an IgG Fc fusion homodimer of the extracellular domain of CTLA-4, which is currently approved therapeutic agent for rheumatoid arthritis, substantially inhibited IL-2 secretion from Jurkat cells, regardless of RGMB expression levels (Fig. 4E). Here, IL2 is linked to rheumatoid arthritis.